Rosuvastatin/fenofibrate

Drug Profile

Rosuvastatin/fenofibrate

Alternative Names: Crestor/TriCor; Tricor/Crestor

Latest Information Update: 24 Jan 2013

Price : $50

At a glance

  • Originator Abbott Laboratories; AstraZeneca
  • Class Antihyperlipidaemics; Fibric acid derivatives; Fluorobenzenes; Propionates; Small molecules; Sulfonamides
  • Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Lipid metabolism disorders

Most Recent Events

  • 11 Jul 2006 Preclinical trials in Lipid metabolism disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top